Group Information: A list of Alzheimer’s Disease Neuroimaging Initiative investigators can be found at http://www.loni.usc.edu/ADNI/Data/ADNI_Authorship_List.pdf.
Accepted for Publication: July 29, 2013.
Published Online: December 30, 2013. doi:10.1001/jamaneurol.2013.4560.
Study concept and design: Desikan, Andreassen, McEvoy, Hyman, Dale.
Acquisition of data: Desikan, Holland, Zetterberg, Dale.
Analysis and interpretation of data: All authors.
Drafting of the manuscript: Desikan, Thompson, Holland, Andreassen, Dale.
Critical revision of the manuscript for important intellectual content: Desikan, Holland, Hess, Brewer, Zetterberg, Blennow, Andreassen, McEvoy, Hyman, Dale.
Statistical analysis: Desikan, Thompson, Dale.
Obtained funding: Dale.
Administrative, technical, or material support: Desikan, Hess, Zetterberg, Andreassen, Dale.
Study supervision: Desikan, Blennow, Andreassen, McEvoy, Dale.
Conflict of Interest Disclosures: Dr Brewer holds stock options in CorTechs Labs Inc and serves on its advisory board, and he receives financial support from the Eli Lilly Biomarker Unit (Amyvid). Dr Brewer also receives research support from General Electric and Janssen Alzheimer Immunotherapy. Dr Blennow has served on the advisory boards for Innogenetics, Eli Lilly, Pfizer, and Roche. Dr McEvoy’s spouse is the chief executive officer of CorTechs Labs Inc. Dr Dale is a founder and holds equity in CorTechs Labs Inc and serves on its scientific advisory board. The terms of this arrangement have been reviewed and approved by the University of California, San Diego, in accordance with its conflict of interest policies. No other disclosures were reported.
Funding/Support: This research was supported by grants from the National Institutes of Health (R01AG031224; K01AG029218; K02 NS067427; and T32 EB005970), the Research Council of Norway (183782/V50), and the South East Norway Health Authority (2010-074). Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health grant U01 AG024904). The ADNI is funded by the National Institute on Aging and the National Institute of Biomedical Imaging and Bioengineering, as well as through contributions from the following: Alzheimer’s Association; Alzheimer’s Drug Discovery Foundation; BioClinica Inc; Biogen Idec Inc; Bristol-Myers Squibb Co; Eisai Inc; Elan Pharmaceuticals Inc; Eli Lilly and Co; F. Hoffmann-La Roche Ltd and its affiliated company Genentech Inc; GE Healthcare; Innogenetics NV; IXICO Ltd; Janssen Alzheimer Immunotherapy Research & Development LLC; Johnson & Johnson Pharmaceutical Research & Development LLC; Medpace Inc; Merck & Co Inc; Meso Scale Diagnostics LLC; NeuroRx Research; Novartis Pharmaceuticals Corp; Pfizer Inc; Piramal Imaging; Servier; Synarc Inc; and Takeda Pharmaceutical Co. The Canadian Institutes of Health Research provides funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (http://www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of California, Los Angeles. This research was also supported by National Institutes of Health grants P30 AG010129 and K01 AG030514.
Role of the Sponsor: The funding agencies had no role in the design and conduct of the study; collection, management, analysis, or interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Additional Contributions: Data used in preparation of this article were obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database (http://adni.loni.ucla.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in the analysis or writing of this article.